Dipeptidyl Peptidase (DPP) is an antigenic enzyme expressed on the surface of most cell types and is associated with immune regulation, signal transduction and apoptosis. DPP is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. The substrates of DPP are proline-containing peptides and include growth factors, chemokines, neuropeptides, and vasoactive peptides. DPP plays a major role in glucose metabolism. DPP is responsible for the degradation of incretins such as GLP-1. Furthermore, DPP appears to work as a suppressor in the development of cancer and tumours. DPP plays an important role in tumor biology, and is useful as a marker for various cancers, with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others.
## Dipeptidyl Peptidase Inhibitors

### 1G244

1G244 is a potent DPP8/9 inhibitor with IC\textsubscript{50} of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPV and DPPI. 1G244 induces apoptosis in multiple myeloma cells and has anti-myeloma effects.

- **Purity:** > 98%
- **Clinical Data:** No Development Reported
- **Size:** 100 mg, 250 mg, 500 mg

### Alogliptin (SYR-322 free base)

Alogliptin (SYR-322 free base) is a potent, selective inhibitor of DPP-4 with IC\textsubscript{50} of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. IC\textsubscript{50} value: <10 nM

- **Target:** DPP4
- **Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class.**
- **Purity:** > 98%
- **Clinical Data:** Launched
- **Size:** 5 mg, 10 mg, 50 mg, 100 mg

### Alogliptin (13CD3)

Alogliptin 13CD3 (SYR-322 13CD3) is the deuterium labeled Alogliptin. Alogliptin is a potent and selective inhibitor of DPP-4.

- **Purity:** > 98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### Anagliptin

Anagliptin is a highly selective, potent inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC\textsubscript{50} of 3.8 nM and less selective at DPP-8/9 (IC\textsubscript{50} 60 nM, respectively).

- **Purity:** 99.72%
- **Clinical Data:** Launched
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 50 mg

### AZD7986

AZD7986 is a potent inhibitor of DPP1 with IC\textsubscript{50} of 6.85, 7.6, 7.7, 7.8, and 7.8 in human, mouse, rat, dog and rabbit, respectively.

- **Purity:** 99.07%
- **Clinical Data:** Phase 1
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### DBPR108

DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC\textsubscript{50} of 15 nM; no inhibition on DDP8 and DPP9.

- **Purity:** 99.90%
- **Clinical Data:** Phase 1
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Diprotin A TFA

Diprotin A TFA (Ile-Pro-Pro (TFA)) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).

- **Purity:** > 98%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

### DPP-IV-IN-1

DPP-IV-IN-1 is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV), a highly specific serine protease, with an IC\textsubscript{50} of 4.6 nM.

- **Purity:** > 98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg, 10 mg, 20 mg

### DPP-IV-IN-2

DPP-IV-IN-2 is an inhibitor of both dipeptidyl peptidase IV (DPP-IV) and DPP8/9 with IC\textsubscript{50} of 0.1 and 0.95 μM, respectively.

- **Purity:** > 98.0%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 50 mg

---

**Tel:** 609-228-6898  **Fax:** 609-228-5909  **Email:** sales@MedChemExpress.com
| **Dutogliptin**  
(PHX-1149 free base) | **Cat. No.: HY-10286** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.</td>
<td></td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Phase 3</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Dutogliptin tartrate**  
(PHX-1149) | **Cat. No.: HY-10286A** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.</td>
<td></td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Evogliptin tartrate**  
(DA-1229 tartrate) | **Cat. No.: HY-117985B** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity. Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation.</td>
<td></td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Gemigliptin**  
(LC15-0444) | **Cat. No.: HY-14892** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemigliptin is a highly selective dipeptidyl peptidase IV (DPP-IV) inhibitor with antidiabetic activity.</td>
<td></td>
</tr>
<tr>
<td>Purity: 98.31%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Gosogliptin**  
(PF-00734200; PF-734200) | **Cat. No.: HY-10287** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gosogliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-IV).</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.27%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Phase 3</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Linagliptin**  
(BI 1356) | **Cat. No.: HY-10284** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Linagliptin is a highly potent, selective DPP-4 inhibitor with IC₅₀ of 1 nM.</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.80%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Launched</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg, 1 g</td>
<td></td>
</tr>
</tbody>
</table>

| **Nateglinide**  
(A4166; Senaglinide) | **Cat. No.: HY-B0422** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.</td>
<td></td>
</tr>
<tr>
<td>Purity: 98.11%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Launched</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 10 mg, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Omarigliptin**  
(MK-3102) | **Cat. No.: HY-15981** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Omarigliptin (MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC₅₀ of 1.6 nM; highly selective over all proteases tested (IC₅₀ &gt; 67 μM).</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.91%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Launched</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prodipine hydrochloride</strong></th>
<th><strong>Cat. No.: HY-101605</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Prodipine, a diphenyl-phosphonate derivative. The IC₅₀ of Prodipine for purified and plasma Dipeptidyl peptidase IV (DPP IV) from the rabbit are 4.5 μM and 30 μM, respectively.</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.50%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

---

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puromycin aminonucleoside (NSC 3056)</td>
<td>HY-15695</td>
<td>Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models. Puromycin aminonucleoside induces apoptosis.</td>
</tr>
<tr>
<td>Purity: 99.59%</td>
<td>Clinical Data: No Development Reported</td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g</td>
</tr>
<tr>
<td>Retagliptin Phosphate (SP 2086)</td>
<td>HY-112668</td>
<td>Retagliptin Phosphate is pharmaceutical composition of DPP-4 inhibitor for treating type-2 diabetes.</td>
</tr>
<tr>
<td>Purity: 99.70%</td>
<td>Clinical Data: No Development Reported</td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Saikogenin A</td>
<td>HY-N6584</td>
<td>Saikogenin A, extracted from a Chinese herbal plant called Tsai-Fu, is a dipeptidyl peptidase-IV (DPP-IV) inhibitor.</td>
</tr>
<tr>
<td>Purity: 98.31%</td>
<td>Clinical Data: No Development Reported</td>
<td>Size: 5 mg</td>
</tr>
<tr>
<td>Saxagliptin Hydrate (BMS-477118 hydrate)</td>
<td>HY-10285A</td>
<td>Saxagliptin H2O (BMS477118 H2O) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM and Ki of 1.3 nM.</td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td>Clinical Data: Launched</td>
<td>Size: 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Saxagliptin (BMS-477118)</td>
<td>HY-10285</td>
<td>Saxagliptin is an orally active dipeptidyl peptidase-4 (DPP4) inhibitor that helps control blood sugar levels.</td>
</tr>
<tr>
<td>Purity: 99.61%</td>
<td>Clinical Data: No Development Reported</td>
<td>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>HY-13749</td>
<td>Sitagliptin is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.</td>
</tr>
<tr>
<td>Purity: 99.72%</td>
<td>Clinical Data: Launched</td>
<td>Size: 10 mM × 1 mL, 100 mg, 200 mg</td>
</tr>
<tr>
<td>Sitagliptin phosphate (MK0431)</td>
<td>HY-13749A</td>
<td>Sitagliptin phosphate is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.</td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td>Clinical Data: Launched</td>
<td>Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate)</td>
<td>HY-13749B</td>
<td>Sitagliptin phosphate monohydrate is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.</td>
</tr>
<tr>
<td>Purity: 99.78%</td>
<td>Clinical Data: Launched</td>
<td>Size: 10 mM × 1 mL, 100 mg, 200 mg</td>
</tr>
<tr>
<td>Talabostat (Val-boroPro; PT100)</td>
<td>HY-13233</td>
<td>Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor [IC50 &lt; 4 nM, Ki = 0.18 nM] and the first clinical inhibitor of fibroblast activation protein (FAP) [IC50 = 560 nM], inhibits DPP8/9 [IC50 = 4/11 nM, Ki = …]</td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td>Clinical Data: Phase 3</td>
<td>Size: 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate)</td>
<td>HY-13233A</td>
<td>Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor [IC50 &lt; 4 nM, Ki = 0.18 nM] and the first clinical inhibitor of fibroblast activation protein (FAP) [IC50 = 560 nM], inhibits DPP8/9 [IC50 = 4/11…]</td>
</tr>
<tr>
<td>Purity: &gt;98.0%</td>
<td>Clinical Data: Phase 3</td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Product Name</td>
<td>Cat. No.</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Teneligliptin (MP-513)</td>
<td>HY-14806</td>
<td>Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC$_{50}$ of approximately 1 nM.</td>
</tr>
<tr>
<td>Purity: 99.57%</td>
<td>Clinical Data:</td>
<td>Launched</td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Teneligliptin D8 (MP-513 D8)          | HY-14806S      | Teneligliptin D8 (MP-513 D8) a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.  |
| Purity: >98%                          | Clinical Data: | No Development Reported                                                                                                                      |
| Size: 1 mg, 5 mg                       |

| Teneligliptin hydrobromide (MP-513 hydrobromide) | HY-14806B | Teneligliptin (MP-513) hydrobromide is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC$_{50}$ of approximately 1 nM.  |
| Purity: 99.99%                         | Clinical Data: | Launched                                                                 |
| Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg |

| Teneligliptin hydrobromide hydrate (MP-513 hydrobromide hydrate) | HY-14806C | Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC$_{50}$ of approximately 1 nM.  |
| Purity: >98%                         | Clinical Data: | No Development Reported                                                                 |
| Size: 10 mg, 50 mg                   |

| Trelagliptin (SYR-472)                | HY-15408      | Trelagliptin (SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).                                                                 |
| Purity: 99.89%                       | Clinical Data: | Launched                                                                 |
| Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

| Trelagliptin succinate (SYR-472 succinate) | HY-15408A | Trelagliptin succinate (SYR-472 succinate) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).                                                                 |
| Purity: 99.89%                       | Clinical Data: | Launched                                                                 |
| Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

| UAMC00039 dihydrochloride             | HY-101769     | UAMC00039 dihydrochloride is a potent, reversible and competitive dipeptidyl peptidase II inhibitor with an IC$_{50}$ of 0.48 nM.                                                                                                                                       |
| Purity: 98.44%                        | Clinical Data: | No Development Reported                                                                                                                   |
| Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

| Vildagliptin (LAF237; NVP-LAF 237)     | HY-14291      | Vildagliptin (LAF-237; NVP-LAF 237) inhibits DPP-4 with IC50 of 2.3 nM. IC50 Value: 2.3 nM Target: DPP-4 in vitro: Vildagliptin is an N-substituted glycyl-2-cyanopyrrolidine (figure 2). |
| Purity: 98.03%                        | Clinical Data: | Launched                                                                 |
| Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg |

| Vildagliptin dihydrate (LAF237 dihydrate; NVP-LAF 237 dihydrate) | HY-14291A | Vildagliptin (LAF237 dihydrate; NVP-LAF 237 dihydrate) is a dipeptidyl peptidase 4 (DPP4) inhibitor that delays the degradation of glucagon-like peptide-1 (GLP-1).                                                                 |
| Purity: >98%                       | Clinical Data: | No Development Reported                                                                                                                    |
| Size: 10 mg, 50 mg, 100 mg         |